Phaseline

Companies › Leukos Biotech

Leukos Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB-208
HTR1B antagonist
HTR1BPhase 1Solid Tumor MalignanciesDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07914348LB-208Phase 1Solid Tumor MalignanciesOncologyDec 2026

Targets

HTR1B (1)

Companies with the same targets

Technophage

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.